Accelrys's Viewer ActiveX control to be integrated into Agilent Life Science informatics offerings for enhanced molecular visualisation and decision support
Agilent Technologies and Accelrys, a wholly owned subsidiary of Pharmacopeia, have announced a software licensing agreement and technology alliance expected to result in software to assist pharmaceutical and biotech professionals in the development of more effective drugs.
Agilent will license the use of Accelrys's Viewer ActiveX control for 3D visualisation of molecular structures.
The Viewer ActiveX control will be integrated into the recently released Agilent Synapsia informatics workbench, and will enable scientists and technicians in the pharmaceutical and biotech industry to visualise and share molecular information in a clear and consistent manner across the pharmaceutical value chain.
It is expected to further enhance the collaborative knowledge synthesising capability of Agilent's informatics software, and therefore help accelerate decision-making in the development of more effective drugs. Accelrys's Viewer ActiveX control visualisation capabilities will be incorporated into new Agilent informatics software products.
"This agreement will enhance Agilent's wide-range of informatics software products used for data management, gene expression, proteomics, drug and disease discovery research," said Chris van Ingen, senior vice president of Agilent's life sciences and chemical analysis business.
"We are pleased to be working with Accelrys to access the best visualisation tools available and further develop software products that reduce the bottleneck of data manipulation and analysis." "This agreement demonstrates our companies' common vision of providing open environments that enable users to select the best tools to suit their research needs," said Scott Kahn, general manager and senior vice president, Accelrys Life Science.
"Through this offering, we aim to provide a level of interconnectivity between Agilent and Accelrys products that will enable them to freely exchange molecular and genetic data.
We believe that the future of accelerated pharmaceutical research is exemplified by the productivity gains inherent in this approach."
